This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by
cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis …

Background Myeloproliferative neoplasms, such as polycythemia vera, essential
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Purpose To develop a prognostic system for transplantation-age patients with primary
myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and …

PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …

Background Approximately 50 to 60% of patients with essential thrombocythemia or primary
myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to …

Ruxolitinib is a Janus kinase (JAK)(JAK1/JAK2) inhibitor that has demonstrated superiority
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with …

International collaborations over the years have produced a series of prognostic models for
primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced …

Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and
reduced survival compared with age-/sex-matched controls. This analysis evaluated the …